A tumor suppressive DNA translocase named FANCM.
Jihane BasbousAngelos ConstantinouPublished in: Critical reviews in biochemistry and molecular biology (2019)
FANCM is named after Fanconi anemia (FA) complement group M. The clinical symptoms of FA include congenital abnormalities, pancytopenia, and cancer proneness. However, recent studies reveal that biallelic inactivation of FANCM does not cause the constellation of FA symptoms, but predisposes patients to cancer and infertility. FANCM is a tumor suppressor gene that encodes a conserved and structure-specific DNA translocase. It controls the outcome of homologous recombination and facilitates DNA replication across a variety of natural and chemically induced obstacles. This review details our current understanding of FANCM as a facilitator of the cellular functions of caretaker proteins, including FA, Bloom syndrome, and Ataxia telangiectasia and RAD3-related proteins, which collectively ensure the maintenance of chromosome stability during DNA replication.
Keyphrases
- papillary thyroid
- dna repair
- dna damage
- end stage renal disease
- circulating tumor
- squamous cell
- newly diagnosed
- ejection fraction
- genome wide
- cell free
- copy number
- prognostic factors
- drug induced
- transcription factor
- type diabetes
- peritoneal dialysis
- high glucose
- polycystic ovary syndrome
- early onset
- young adults
- nucleic acid
- endothelial cells
- patient reported outcomes
- case report
- insulin resistance